Skip to content
Back to the Guavy Wire
Stocks

PTAB Invalidates Halozyme Patents in Merck Keytruda Dispute

Instruments
MRK
Share

The Patent Trial and Appeal Board (PTAB) has invalidated claims in two Halozyme Inc. patents that the company had accused Merck Sharp & Dohme LLC of infringing with its cancer treatment Keytruda. This decision marks the 14th successful PTAB challenge for Merck in its ongoing legal dispute with Halozyme.

The ruling reduces the number of patents Halozyme can assert against Merck's blockbuster drug, Keytruda. The PTAB's decision is part of a broader legal battle between the two companies over patent infringement claims related to the cancer treatment.

Merck has been actively challenging Halozyme's patents through the PTAB, aiming to invalidate claims that could impact the commercialization of Keytruda. The latest ruling continues Merck's streak of successful challenges in this high-stakes legal feud.

More on Stocks